A Multi-centre, One-arm Prospective Study to Evaluate Efficacy and Safety of Switching From Entecavir (ETV) to Tenofovir Disoproxil Fumarate (TDF) in Japanese Chronic Hepatitis B HBeAg-positive and HBV-DNA Undetectable Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs Tenofovir dipivoxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 27 Feb 2018 Planned primary completion date changed from 29 Dec 2018 to 26 Dec 2018.
- 27 Feb 2018 Planned primary completion date changed from 30 Nov 2019 to 29 Dec 2018.
- 27 Feb 2018 Status changed from recruiting to active, no longer recruiting.